CSPC Pharmaceutical Group Ltd (CHPTY) Rating Increased to Hold at Zacks Investment Research
CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “
Shares of CSPC Pharmaceutical Group (NASDAQ CHPTY) remained flat at $73.27 during midday trading on Thursday. The company has a market capitalization of $8.87 billion and a price-to-earnings ratio of 29.31. The company has a 50 day moving average price of $73.27 and a 200-day moving average price of $68.45. CSPC Pharmaceutical Group has a one year low of $50.09 and a one year high of $73.36.
CSPC Pharmaceutical Group Company Profile
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with MarketBeat.com's FREE daily email newsletter.